SPH5030

Phase 2Small molecule

SShanghai Pharmaceuticals Holding Co., Ltd

SPH5030 is one of 51 small molecule programs targeting HER2-Positive Solid Tumor. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HER2-Positive Solid TumorRecruiting

Colorectal CancerRecruiting

HER2-Positive Solid TumorPhase 1

Recruiting

Colorectal CancerPhase 2

Recruiting

Competition

Competitive Landscape

268 competitors in Colorectal Cancer

#DrugCompanyPhaseTrials

Stivarga

Bayer

Phase 3

39 2

Opdivo

Bristol-Myers Squibb

Phase 3

24 3

Adrucil

EElorac, Inc.

Phase 3

87 4

Wellcovorin

EEastern Cooperative Oncology Group

Phase 3

58 5

Acetylsalicylic Acid

Bayer

Phase 3

7 6

Trifluridine/tipiracil

AbbVie

Phase 3

3 7

Telisotuzumab Adizutecan

AbbVie

Phase 3

2 8

XL092

Roche

Phase 3

1 9

TAS 102

Taiho Oncology, Inc.

Phase 3

8 10

5-Fu

TToray Industries, Inc

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Colorectal Cancer

NCT06434597

Clinical

Trials by Indication[1]

Colorectal Cancer1 trial

A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.

Recruiting·SShanghai Pharmaceuticals Holding Co., Ltd·Phase 2·NCT06434597·60 enrolled

HER2-Positive Solid Tumor1 trial

SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors

Recruiting·SShanghai Pharmaceuticals Holding Co., Ltd·Phase 1·NCT05245058·150 enrolled

Unspecified1 trial

A Food Effect Study of SPH5030 Tablets.

Completed·SShanghai Pharmaceuticals Holding Co., Ltd·Phase 1·NCT06372223·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for SPH5030. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SPH5030 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SPH5030. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Pharmaceuticals Holding Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SShanghai Pharmaceuticals Holding Co., Ltd

SPH5030

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Colorectal Cancer1 trial

HER2-Positive Solid Tumor1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News